מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
FLUDARABINE PHOSPHATE (FLUDARABINE PHOSPHATE SODIUM)
SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC
L01BB05
FLUDARABINE
50MG
POWDER FOR SOLUTION
FLUDARABINE PHOSPHATE (FLUDARABINE PHOSPHATE SODIUM) 50MG
INTRAVENOUS
2ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0123842001; AHFS:
CANCELLED POST MARKET
2011-03-31
_ _ _ _ _Page 1 of 49 _ PRODUCT MONOGRAPH PR FLUDARA ® fludarabine phosphate for injection 50 mg per vial as sodium salt and fludarabine phosphate tablets 10 mg Antineoplastic Genzyme Canada Inc. 800-2700 Matheson Blvd. East, West Tower Mississauga, ON L4W 4V9 Canada www.genzyme.ca DATE OF REVISION: April 19, 2011 SUBMISSION CONTROL NO: 143857 © 2009, Genzyme Canada Inc. ® FLUDARA is a registered trademark exclusively licensed to Genzyme Corporation. _ _ _ _ _Page 2 of 49 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................8 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION..............................................................................11 OVERDOSAGE ................................................................................................................12 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY..........................................................................................14 SPECIAL HANDLING INSTRUCTIONS .......................................................................15 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................15 PART II: SCIENTIFIC INFORMATION ................................................................................17 PHARMACEUTICAL INFORMATIO קרא את המסמך השלם